Art. -Nr.: HY-14538

Haloperidol

22 Cited Publications

Kundenbewertung

Based on 22 publication(s) in Google Scholar

Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic agent. Haloperidol can be used in the study of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.69%
CAS. Nr.: 52-86-8
Formel: C₂₁H₂₃ClFNO₂
Molecular Weight:375.86

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Haloperidol Chemical Structure

CAS. Nr.: 52-86-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- Induced Disease Models
- Clinical Trial
Chemical Information
Publications (22)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

D₂ Receptor

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	>20 μM Compound: Haloperidol	Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining	[PMID: 19243173]
5637	IC₅₀	2.3 μM Compound: Haloperidol	Growth inhibition of human 5637 cells incubated for 96 hrs by crystal violet assay Growth inhibition of human 5637 cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
A-427	IC₅₀	10 μM Compound: Haloperidol	Growth inhibition of human A427 cells after 96 hrs Growth inhibition of human A427 cells after 96 hrs	[PMID: 17967001]
A-427	IC₅₀	10 μM Compound: Haloperidol	Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining	[PMID: 19243173]
A-427	IC₅₀	9.6 μM Compound: Haloperidol	Growth inhibition of human A427 cells incubated for 96 hrs by crystal violet assay Growth inhibition of human A427 cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
CHO	IC₅₀	32 nM Compound: haloperidol	Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1 Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1	[PMID: 12729675]
CHO	IC₅₀	1.1 μM Compound: Haloperidol	Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay	[PMID: 22677319]
CHO	IC₅₀	1.3 μM Compound: haloperidol	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
CHO	IC₅₀	4.8 nM Compound: Haloperidol	Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand	[PMID: 8759642]
CHO	IC₅₀	0.006 μM Compound: haloperidol	Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells	[PMID: 8831770]
CHO-hD3	IC₅₀	8.8 nM Compound: Haloperidol	Compound was tested for stimulation of mitogenesis in CHO.hD3 cells in a dose dependent manner Compound was tested for stimulation of mitogenesis in CHO.hD3 cells in a dose dependent manner	[PMID: 9873609]
CHO-K1	IC₅₀	5500 nM Compound: 5	Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells	[PMID: 10377229]
CHO-K1	IC₅₀	0.16 nM Compound: Haloperidol	Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay	[PMID: 25126833]
CHO-K1	IC₅₀	5500 nM Compound: haloperidol	Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells	[PMID: 9406603]
DAN-G	IC₅₀	>20 μM Compound: Haloperidol	Growth inhibition of human DAN-G cells incubated for 96 hrs by crystal violet assay Growth inhibition of human DAN-G cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
HEK293	EC₅₀	>10000 nM Compound: Haloperidol	Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5 Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5	[PMID: 15380206]
HEK293	IC₅₀	141.9 μM Compound: haloperidole	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HEK293	IC₅₀	0.23 μM Compound: haloperidol	Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay	[PMID: 22694270]
HEK293	IC₅₀	0.55 μM Compound: Haloperidol	Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay	[PMID: 23332346]
HEK293	IC₅₀	0.7 nM Compound: Haloperidol	Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay	[PMID: 24831693]
HEK293	IC₅₀	1.16 μM Compound: Haloperidol	Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay	[PMID: 32392053]
HL-60	IC₅₀	>20 μM Compound: Haloperidol	Growth inhibition of human HL60 cells incubated for 48 hrs by MTT assay Growth inhibition of human HL60 cells incubated for 48 hrs by MTT assay	[PMID: 27156565]
Jurkat	IC₅₀	230 nM Compound: haloperidol	Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in human Jurkat cells by scintillation counting Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in human Jurkat cells by scintillation counting	[PMID: 19875205]
Jurkat	IC₅₀	0.021 μM Compound: haloperidol	Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells after 4 hrs Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells after 4 hrs	[PMID: 23403082]
Jurkat	IC₅₀	1.7 x 10^-8 M Compound: Haloperidol	Displacement of [3H]DTG from sigma receptor in human jurkat cells Displacement of [3H]DTG from sigma receptor in human jurkat cells	[PMID: 26988801]
Jurkat	IC₅₀	1.7 x 10^-8 M Compound: Haloperidol	Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method	[PMID: 27876250]
Jurkat	IC₅₀	1.7 x 10^-2 μM Compound: Haloperidol	Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method	[PMID: 27876250]
LCLC-103H cell line	IC₅₀	>20 μM Compound: Haloperidol	Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining	[PMID: 19243173]
LCLC-103H cell line	IC₅₀	10.9 μM Compound: Haloperidol	Growth inhibition of human LCLC-103H cells incubated for 96 hrs by crystal violet assay Growth inhibition of human LCLC-103H cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
MCF7	IC₅₀	24.9 μM Compound: Haloperidol	Growth inhibition of human MCF7 cells after 96 hrs Growth inhibition of human MCF7 cells after 96 hrs	[PMID: 17967001]
MCF7	IC₅₀	>20 μM Compound: Haloperidol	Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining	[PMID: 19243173]
MCF7	IC₅₀	>20 μM Compound: Haloperidol	Growth inhibition of human MCF7 cells incubated for 96 hrs by crystal violet assay Growth inhibition of human MCF7 cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
MCF7	IC₅₀	20.17 μM Compound: Haloperidol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31042618]
MCF7	IC₅₀	68 μM Compound: Halo	Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay	[PMID: 35724925]
RT-4	IC₅₀	>20 μM Compound: Haloperidol	Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining	[PMID: 19243173]
RT-4	IC₅₀	16 μM Compound: Haloperidol	Growth inhibition of human RT4 cells incubated for 96 hrs by crystal violet assay Growth inhibition of human RT4 cells incubated for 96 hrs by crystal violet assay	[PMID: 27156565]
ScN2a	EC₅₀	>10 μM Compound: Haloperidol	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	[PMID: 12904059]
SK-BR-3	IC₅₀	131 μM Compound: Halo	Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay	[PMID: 35724925]
U2OS	IC₅₀	0.06 nM Compound: Haloperidol	Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay	[PMID: 25126833]

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Haloperidol can be used to create tardive dyskinesia models. In rats, the oral half-life of Haloperidol is 5.9 hours, with a Tmax of 0.9 hours, a Cmax of 6.8 ng/mL, and an oral bioavailability of 23.0%. When administered intravenously, the AUC_0-∞ of Haloperidol is 188.4 ng·h/mL, and the t_1/2 is 2.9 hours^[3].

Induction oftardive dyskinesia^[4]

Background

Haloperidolreduces gene expression of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GHP), thus reducing the complex cellular antioxidant defenses and increasing lipid peroxidation and nitrite/nitrate levels in the prefrontal cortex, hippocampus, and striatum^[4].

Specific Modeling Methods

Rat: 200-350 g • male Wistar
Administration: 1 mg/KG • i.p. • daily for 31 days

Modeling Indicators

Behavior: Showed a significant reduction of locomotor activity in the open field test and also developed a cataleptic state, vacuous chewing movements (VCM), and tongue protrusion.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 52-86-8
Appearance Solid
Molecular Weight 375.86
Formel C₂₁H₂₃ClFNO₂
Color White to off-white
SMILES

ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (22)

All WBCell Proliferation/Viability AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Cell

Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. [Abstract]

2023 Nov 22;186(24):5347-5362.e24. PMID: 37963465
Adv Sci (Weinh)

Dopamine D1 Receptor Contributes to Glucocorticoid-Associated Osteonecrosis of Femoral Head Protection Through the ATF3/CHOP Axis to Inhibit Osteoblastic Apoptosis. [Abstract]

2025 Sep;12(33):e02276. PMID: 40583147

Haloperidol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(33):e02276. [Abstract]

Western blotting of DRD1, ALP, OCN, BAX, Bcl2, cleaved‐caspase3, and β‐actin in osteogenesis‐induced BMSCs treated with Haloperidol (1 µM), DA and then stimulated with MP.
Environ Sci Technol

2-Ethylhexyl Diphenyl Phosphate Causes Obesity in Zebrafish by Stimulating Overeating via Inhibition of Dopamine Receptor D2. [Abstract]

2023 Sep 26;57(38):14162-14172. PMID: 37704188
Acta Biomater

Carrier-free spherical nucleic acids engineered by coordination-competition for programmable release and cancer immunotherapy. [Abstract]

2026 Jun:216:333-347. PMID: 41962730
Phytomedicine

Valproic acid promotes transcriptional activation of Drd2 by mediating histone acetylation to inhibit the mTOR-Pttg1 signaling axis and exerts anti-PitNETs activity. [Abstract]

2025 Jun:141:156707. PMID: 40220407
Br J Pharmacol

Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas. [Abstract]

2021 Sep;178(17):3570-3586. PMID: 33904172
Oncogenesis

Peroxisomal lipid metabolism inhibits Pimozide-induced cancer cell death by regulating ATP homeostasis. [Abstract]

2025 Aug 21;14(1):31. PMID: 40841534
EMBO Rep

ZFP207 sustains pluripotency by coordinating OCT4 stability, alternative splicing and RNA export. [Abstract]

2022 Feb 3;23(3):e53191. PMID: 35037361
J Ethnopharmacol

Total barley maiya alkaloids inhibit prolactin secretion by acting on dopamine D2 receptor and protein kinase A targets. [Abstract]

2021 Jun 12:273:113994. PMID: 33711439
Eur J Pharmacol

A novel dopamine D2 receptor-NR2B protein complex might contribute to morphine use disorders. [Abstract]

2023 Dec 15:961:176174. PMID: 37939993
Eur J Pharmacol

Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919). [Abstract]

2023 May 5:946:175647. PMID: 36898424
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
ACS Omega

Involvement of Integrated Stress Response in Drug-Induced Secondary Dystonia. [Abstract]

2025 Oct 17;10(42):50208-50217. PMID: 41179162

Haloperidol purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Oct 17;10(42):50208-50217. [Abstract]

Haloperidol (Halo; 20 ng/mL; 24 h). ISR induction by various drugs. N2a cells were treated with the indicated drugs for 24 h. The cell extracts were analyzed by Western blot analysis with anti-ATF4, anti-CHOP, and anti-β actin antibodies.
ACS Omega

Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. [Abstract]

2020 Nov 15;5(46):29935-29942. PMID: 33251429
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
BMC Endocr Disord

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. [Abstract]

2021 Nov 23;21(1):235. PMID: 34814904
Clin Exp Pharmacol Physiol

Dopamine receptor D2 inhibition alleviates diabetic hepatic stellate cells fibrosis by regulating the TGF-β1/Smads and NFκB pathways. [Abstract]

2021 Mar;48(3):370-380. PMID: 33179312

Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]

Haloperidol (10 μM; 48 h). Cell viability was measured by CCK-8 assay. The cells incubated with control medium were considered 100% viable.

Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]

Haloperidol (10 μM; 48 h). ROS production in HSCs measured by staining with DCFH-DA and imaged by fluorescent microscopy.

Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]

Haloperidol (10 μM; 48 h). Immunoblotting and optical density analysis of DRD2 and NOX-5, and the data were normalized to GAPDH.
Behav Brain Res

Activation of dopamine D2 receptors in the shell of nucleus accumbens triggers conditioned avoidance responses in rats. [Abstract]

2022 Mar 26:422:113759. PMID: 35051488
Eur J Integr Med

2021, 101322.
Clin Tradit Med Pharmacol

2026 Jan 14.
University of South Carolina

2025.
University of Zurich

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 40 mg/mL (106.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6606 mL

13.3028 mL

26.6057 mL

5 mM

0.5321 mL

2.6606 mL

5.3211 mL

10 mM

0.2661 mL

1.3303 mL

2.6606 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (4.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (4.44 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (4.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[2]

Male albino mice of Swiss-Webster strain (33-36 g) are used, and all substances are given by i.p. injection in a volume of 0.5 mL. CPZ, haloperidoi and mescaline are all in time form of timeir imydrochlorides and the dose solutions are prepared at concentrations of 1.0, 0.66 and 3.3 mg/mL of 0.9% saline, respectively. The doses are: CPZ, 15 mg/kg; haloperidol, 10 mg/kg; mescaline, 50 mg/kg. Mice are pretreated with either CPZ or haloperidol 30 minutes before administration of mescaline. In some instances CPZ is injected 45 minutes after mescaline. Time animals are hmoused individually in a plexiglas cage and the gross behavior and locomotor activity. At selected intervals after mescaline, groups of mice are sacrificed by decapitation. Plasma is separated and stored at -20°C. The brain, liver, kidney, lung, spleen and heart are frozen on dry ice and stored at -20°C for 18 to 20 hours before they are used for assays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Furuta Y, et al. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs. Br J Pharmacol. 1973 Jan;47(1):77-84 [Content Brief]

[2]. Shah NS, et al. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice. J Pharmacol Exp Ther. 1973 Aug;186(2):297-304 [Content Brief]

[3]. Lei K, et al. Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. Exp Anim. 2018 May 10;67(2):163-173. [Content Brief]

[4]. Guzen FP, et al. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. Curr Protoc Neurosci. 2019 Jun;88(1):e68. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6606 mL	13.3028 mL	26.6057 mL	66.5141 mL
	5 mM	0.5321 mL	2.6606 mL	5.3211 mL	13.3028 mL
	10 mM	0.2661 mL	1.3303 mL	2.6606 mL	6.6514 mL
	15 mM	0.1774 mL	0.8869 mL	1.7737 mL	4.4343 mL
	20 mM	0.1330 mL	0.6651 mL	1.3303 mL	3.3257 mL
	25 mM	0.1064 mL	0.5321 mL	1.0642 mL	2.6606 mL
	30 mM	0.0887 mL	0.4434 mL	0.8869 mL	2.2171 mL
	40 mM	0.0665 mL	0.3326 mL	0.6651 mL	1.6629 mL
	50 mM	0.0532 mL	0.2661 mL	0.5321 mL	1.3303 mL
	60 mM	0.0443 mL	0.2217 mL	0.4434 mL	1.1086 mL
	80 mM	0.0333 mL	0.1663 mL	0.3326 mL	0.8314 mL
	100 mM	0.0266 mL	0.1330 mL	0.2661 mL	0.6651 mL

Keywords

Haloperidol

22 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Haloperidol

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Dopamine Receptor Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

Chinese Baijiu Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Haloperidol

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Haloperidol Related Classifications

HY-14538 Related Classifications